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Abstract The recommended dose of IgG in primary immu-
nodeficiency (PID) has been increasing since its first use.
This study aimed to determine if higher subcutaneous IgG
doses resulted in improved patient outcomes by comparing
results from two parallel clinical studies with similar design.
One patient cohort received subcutaneous IgG doses that
were 1.5 times higher than their previous intravenous doses
(mean 213 mg/kg/week), whereas the other cohort received
doses identical to previous subcutaneous or intravenous
doses (mean 120 mg/kg/week). While neither cohort had
any serious infections, the cohort maintained on higher mean
IgG dose had significantly lower rates of non-serious infec-
tions (2.76 vs. 5.18 episodes/year, P<0.0001), hospitalization
(0.20 vs. 3.48 days/year, P<0.0001), antibiotic use (48.50 vs.
72.75 days/year, P<0.001), and missed work/school activity
(2.10 vs. 8.00 days/year, P<0.001). The higher-dose cohort
had lower health care utilization and improved indices of well
being compared to the cohort treated with traditional IgG
doses.
Keywords Primaryimmunodeficiency.subcutaneousIgG
replacementtherapy.infectionrate.hospitalizationrate.
Hizentra
Introduction
Injection of immunoglobulins in its initial form was devel-
oped during the 1940s for use in the war effort [1] and was
first used for primary immunodeficiency (PID) as a subcu-
taneous (SC) injection in 1952 by Dr. Ogden C. Bruton [2].
Sincethen, neither anoptimal dosenor serum troughlevel has
been established [3]. From the 1950s through the 1970s,
Janeway and others administered IgG by intramuscular (IM)
injections with doses of 25 mg/kg/week or 100 mg/kg/month,
resultinginserumlevelsof110to260mg/dL,eventhoughthe
landmark British Medical Research Council (MRC) study
found that higher doses resulted in better outcomes [4]. In
the early 1980s,introductionofIgGpreparationsthatcould be
safely given intravenously (intravenous IgG, IVIG) made it
possible to administer higher doses without severe reactions
[5]. As IVIG and newer SC preparations of IgG (SCIG) were
being adopted, the consensus regarding the optimal dose
gradually grew to 400–800 mg/kg/month to achieve serum
levels of 500 mg/dL or greater.
One potential reason for the continued evolution of the
optimal IgG dose may be that the objectives of treatment
have been changing through the decades, as studies showed
that higher IV doses which yielded higher serum trough
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infection. The World Health Organization (WHO) defines
“health” to be a state of “complete physical, mental and
social well being and not merely the absence of disease or
infirmity” [6]. Given that serious infections are efficiently
prevented by IgG replacement, other outcomes that measure
productivity, well being, and health utilization have been
introduced in trials as measures for the comprehensive
WHO definition of health [6]. In addition, immunologists
often raise the dose to try to prevent progression of chronic
lung disease and other end-organ complications of PID.
The PID Committee of the American Academy of Allergy,
Asthma, and Immunology (AAAAI) concluded in a 2006
report that the dose of IgG should be titrated to achieve a
trough level greater than 500 mg/dL in agammaglobulinemic
patientsandthattroughlevelsgreaterthan800mg/dLhavethe
potentialtoimprovepulmonaryoutcomes[7]. There havebeen
few dose-ranging studies with IgG. In most recent licensing
trials, the dose of IgG is based on the patients' previous
treatment regimens without specifying how those doses were
chosen by the patients' individual physicians. A survey of
immunologists conducted recently by the AAAAI found that
those immunologists who devote less than 10% of their prac-
tice to PID usually target a serum level of 500 to 750 mg/dL,
whereas more experienced immunologists whose PID patient
population exceeds 10% of their practice were significantly
more likely to target serum levels above 750 mg/dL (P00.02)
[8].
In 2010, the Canadian Blood Services published their
review of dose-ranging studies and agreed that seven of
the eight articles they reviewed concluded that outcomes
were improved with higher doses of IVIG. Nevertheless, the
authors concluded that although higher doses and serum
trough levels appear to be associated with improved clinical
response, clinical outcomes such as frequency of infections
and days missed from school and work should be used to
monitor the effectiveness of IgG therapy [9]. Recently,
Lucas et al. showed, in a cohort of 90 patients mostly with
common variable immunodeficiency (CVID), that the
ranges of both IgG dose and IgG trough level were very
large and that the goal of replacement therapy should be to
improve clinical outcome and not to reach a particular IgG
trough level [10]. Recent pooled analyses of multiple studies
showed continuous relationships between IgG levels and in-
cidence of pneumonia or other infections, with no sharp break
pointsorplateaus[11,12].AlsoBonaguraetal.suggestedthat
each patient has his/her own “biologic level” above which he/
she is infection-free [13]. Noguidelines haveidentified a dose
or serum level of IgG at which no additional clinical benefit is
achieved, yet several payors have developed their own guide-
linestolimitreimbursementforIgGtoonlythedoseneededto
achieve a given serum IgG level regardless of the patient's
clinical response. Other factors, such as periodic short
supplies of IgG, have also limited the prescribing of higher
doses of IgG and raising of IgG trough levels in PID patients
to achieve optimal clinical responses.
The purpose of this analysis was to determine if there is a
relationship between the use of a higher SC dose of IgG and
improvements in patient outcomes such as missed work/
schooldays,hospitaldays,daysofantibioticuse,andinfection
rate.EuropeanandUShealthauthoritiesrequiredtwodifferent
dosing levels for Hizentra® in their registration trials. This
presented an opportunity to compare the outcomes from these
independent cohorts of patients treated with different doses.
This is the first analysis comparing patient outcomes achieved
with two different SC dosing levels of Hizentra®, a recently
approved 20% IgG preparation for SC use.
Methods
The two independent patient cohorts were from two clinical
trials conducted roughly in parallel, one in the USA and the
other primarily in the European Union (EU), both of which
shared many features of patient selection and study design
as part of a single clinical development program (Table I).
Both studies used an open-label, multi-center, single-arm
design. The EU study enrolled patients from September
2007 to August 2009 [14]. Patients qualified for the study
if they were male or female, aged from 2 to 65 years, and
diagnosed with primary humoral deficiency as defined by
the Pan-American Group for Immunodeficiency (PAGID)
and the European Society for Immunodeficiencies (ESID)
[15]. Prior to being enrolled in the European study, patients
had to be successfully maintained on a stable (variation in
dose not to exceed 10%) IV or SC dose of IgG of 200–
800 mg/kg/month, to have at least three documented pre-
study serum IgG trough levels of ≥500 mg/dL, and to have
experienced an acceptable clinical response as judged by
their physician. Study patients were converted to an equiv-
alent dose of Hizentra® administered weekly by the SC
route. This patient population is referred to as the “1:1 dose”
cohort. After a 12-week wash-in/wash-out phase, patients
entered the 28-week efficacy period where the dose was
held constant (1:1 dose) and outcomes were monitored.
The second cohort of patients came from a study that was
conducted in the USA from November 2006 through October
2008 [16]. The study had similar pre-enrollment requirements
for a stable pre-study dose with an acceptable clinical out-
come. As requested by the US Food and Drug Administration
(FDA), the dose for the 52-week efficacy phase was individ-
ually adjustedto give values for area under the curve of serum
IgG vs. time (AUC) during SCIG therapy, which were equal
to those recorded while the patients were still on the IV
regimens prescribed by their physicians before enrollment.
This resulted in a mean 1.5-fold increase in the SCIG dose
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studydesignsarepresentedintheindividualpublicationsfully
describing each study's effect on traditional endpoints such as
infection rates and safety [14, 16].
The following secondary efficacy outcomes were
assessed in both trials: missed work/school days due to
infection, hospitalization days due to infection, and days of
antibiotic therapy. These outcomes were reported as rate
(days/patient/year) for the wash-in/wash-out and efficacy
periods and served as the basis for this report. Local toler-
ability was assessed differently in the two studies. In the EU
study, only patient's perception 24–72 h after the adminis-
tration was recorded, while in the US study, the investigator
assessed local tolerability within 15–45 min of the end of
the infusion in addition to the patient's perception.
Differences in the distribution of categorical variables
between the two cohorts were compared using Chi-square
test. Mean age, weight, IgG dose, and serum IgG trough
levels were compared using Student's t-test. The rates of
infection, hospitalization, antibiotic use, and missed work/
school days were compared between cohorts using Poisson
regression, with and without controlling for key demo-
graphic differences between the cohorts, i.e., sex, age
group (2–16/≥17 years), and PID type (XLA/CVID and
other) using the days within the study as offset. The
factor PID type was dropped from the multi-factorial analysis
for hospitalization due to convergence problems. All analyses
were performed using SAS Version 9.2 of the SAS System,
SAS Institute Inc., Cary, NC, USA. A level of significance of
5% was set. No adjustment for multiplicity and no checks of
model assumptions were performed.
Results
The characteristics of the two patient cohorts are summarized
in Table II. Because similar study protocols were used to
recruit patients from different continents, the two patient pop-
ulations were generally similar. However, the EU population
included more male, pediatric, and X-linked agammaglobu-
linemia (XLA) patients.
In the EU study, the mean weekly IgG dose adminis-
tered during the efficacy period was 120 mg/kg (range
59–243 mg/kg), resulting in a mean trough level of
810 mg/dL (standard deviation [SD] 144 mg/dL). In the
US study, the mean weekly IgG dose administered during the
efficacy period was 213 mg/kg (range 72–379 mg/kg), result-
ing in a mean trough level of 1,253 mg/dL (SD 321 mg/dL).
Of note, patients in the EU cohort had received lower mean
IgG doses during their previous therapy (mean ± SD 107±
29 mg/kg/week for IVIG treatment and 132±50 mg/kg/week
for SCIG) compared with patients in the US cohort (145±
48 mg/kg/week).
Noseriousbacterialinfectionswerereportedineitherstudy
(Table III). However, the rate of other infections was 2.76
events/patient/year in the 1.5:1 dose cohort vs. 5.18 events/
patient/year in the 1:1 dose cohort (P<0.0001). The rate of
dayshospitalizedinthe1.5:1dosegroupwas0.2days/patient/
year vs. 3.48 days/patient/year in the 1:1 dose group
(P<0.0001). The proportion of patients who became hospital-
ized was lower in the 1.5:1 dose group (2.6 compared to 8.7
for the 1:1 cohort); however, the difference observed was not
statistically significant (P00.2423). The rate of days of anti-
biotic use was 48.50 days/patient/year in the 1.5:1 dose group
Table I Comparison of the Hizentra® US and EU clinical registration trials
Hizentra® trial enrolling patients primarily
from the EU
Hizentra® trial enrolling patients from the USA
Pre-trial requirements ￿ 6 months of stable outcomes ￿ 6 months of stable outcomes
￿ Stable IV or SC IgG dosing ￿ Stable IV IgG dosing
￿ 3 trough levels ≥500 mg/dL ￿ 3 trough levels ≥500 mg/dL
Inclusion/exclusion criteria Same [14] Same [16]
Wash-in/wash-out period 12 weeks 12 weeks
Hizentra® dose during
wash-in/wash-out period
Equivalent to pre-trial IgG dose 1.3 times the pre-trial IgG dose
Efficacy period 28 weeks 52 weeks
Hizentra® dose during efficacy period Equivalent to pre-trial IgG dose (1:1 dose) 1.5 times the pre-trial IgG dose
a (1.5:1 dose)
Outcomes measured Same (IgG trough levels, rate of infections,
hospitalization days, days of antibiotic use,
and missed work/school days)
Same (IgG trough levels, rate of infections,
hospitalization days, days of antibiotic use,
and missed work/school days)
aBased on a US FDA-mandated dose adjustment coefficient determined in pharmacokinetic sub-study [27] to maintain area under the
concentration-time curve following switch from IVIG
EU European Union, IV intravenous, SC subcutaneous, US United States
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Work/school days were missed at a rate of 2.06 days/patient/
year in the 1.5:1 dose group vs. 8.00 in the 1:1 dose group
(P<0.001). The proportion of patients missing one or more
work/school days per year was lower in the 1.5:1 dose cohort,
but the difference observed did not reach statistical signifi-
cance (P00.2637). The results of the EU study were substan-
tially affected by the data of a child with recurrent pneumonia
who missed 71 work/school days and spent 63 days in hospi-
tal [14, 17]. Therefore, a sensitivity analysis excluding this
child was performed. The results of this analysis were similar
to those for the entire populations (Table III).
An analysis of rate of infection by month of the year was
performed to account for the different duration of the two
studies. The results showed an even distribution of onset of
infections over the year in the US study (infection rate
range, 1.14–3.82 infections/patient/year), while a seasonal
variability was noted in the EU study. In the EU study, the
rate of infection by month of onset ranged between 2.27 and
11.21 infections/patient/year, with the lowest rates of infection
observed in June (2.27 infections/subject/year) and July (2.71
infections/subject/year)andthehighestratesinJanuary(11.21
infections/subject/year) and December (9.34 infections/sub-
ject/year).However,theoverallratesofinfectiondidnotshow
any particular trend; thus, the rates for September, October,
and November were similar to those for February, April, and
August (5.17–6.65).
The rate of non-serious infections was significantly differ-
entbetweenthetwocohorts.Toanalyzefurtherthereasonsfor
this difference, an analysis of infection rates in patients expe-
riencing more than four infections during the efficacy periods
of the two studies was performed (Table IV). A substantial
contribution to the annualized rate of infections in the EU
study was due to 12 patients who experienced a total of 79
infection episodes in the efficacy period, resulting in a statis-
ticallysignificantdifferencebetweenthetwocohorts(12.05in
the 1:1 cohort and 8.38 in the 1.5:1 cohort; P00.0430). In the
1.5:1 cohort (USA), seven patients experienced a total of 51
infection episodes (Table IV).
Because the two cohorts differed in gender, age, and PID
type, a Poisson regression was conducted by controlling
these differences as covariates in the analysis across the
efficacy period of each study. The results of this analysis
confirmed the significant differences in all four study
Table II Summary of baseline
and dosing characteristics of
the patients in each trial
ARAG autosomal recessive
agammaglobulinemia, CVID
common variable immunodefi-
ciency, EU European Union,
N/A not applicable, SD standard
deviation, US United States,
XLA X-linked
agammaglobulinemia
aChi-square test
bStudent's t-test
cMean of individual patient
median values
Parameter 1:1 dose cohort
(EU) (N046)
1.5:1 dose cohort
(US) (N038)
P-value of differences
between cohorts
Gender (%)
Female 33 55 0.0368
a
Male 67 45
Age (years)
Mean (SD) 21.5 (15.6) 36.3 (19.5) 0.0003
b
Age group (%)
2–11 years 37 8 0.0134
a
2–16 years 50 24
>16 years 50 76
Weight (kg)
Mean (SD) 52.1 (24.7) 70.0 (21.3) 0.0006
b
PID diagnosis (%)
CVID 61 95 0.0014
a
XLA 37 5
ARAG 2 0
Mean weekly doses before
study start (mg/kg)
122 144 N/A
Median IgG levels before
study start (mg/dL)
N/A
Mean
c (SD) 749 (157) 1,010 (257)
Weekly dose of Hizentra®
during the efficacy period
(mg/kg)
Mean
c (range) [SD] 120 (59–243) [34] 213 (72–379) [78] <0.0001
b
Mean trough level during the
efficacy period (mg/dL)
Mean
c (SD) 810 (144) 1,254 (322) <0.0001
b
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trolling for thelength oftheobservationperiod wasperformed
to compare the 1.5:1 and 1:1 cohorts up to the 28-week time
point. During the first 28 weeks of the efficacy period in the
1.5:1 cohort, the rates of infection (2.7 events/patient/year),
hospitalization (0 days/patient/year), antibiotic use (49.5 days/
patient/year), and missed work/schooldays(1.61 days/patient/
year) were similar to thoseobservedduringtheentire54-week
efficacy period. Consequently, all efficacy outcomes observed
in the 1.5:1 dose group were improved compared to those in
the 1:1 dose group, regardless of the length of the observation
period.
The most common adverse event reported in each study
was local reactions at the injection site. The rate of local
reactions was 0.59 events/infusion in the 1.5:1 cohort and
0.06 events/infusion in the 1:1 cohort. Most of the local
reactions were of mild or moderate intensity (99.7% in the
1.5:1 cohort and 99.1% in the 1:1 cohort). The difference in
the rate of local reactions between the studies was likely due
to the different assessment of local tolerability.
Table III Comparison of health outcomes in the two cohorts of PID patients treated with different doses of subcutaneous Hizentra®
1:1 dose cohort
(EU) (N046)
1.5:1 dose cohort
(US) (N038)
Analysis of differences between cohorts
Univariate
comparisons
Multi-factorial comparisons
adjusting for covariables
Rate of serious infections (events/patient/year) 0 0
Rate of infections (events/patient/year) 5.18 2.76 <0.0001
b <0.0001
b
Sensitivity analysis
a 5.16 <0.0001
b <0.0001
b
Rate of days of hospitalization due to infection
(days/patient/year)
3.48 0.20 <0.0001
b <0.0001
b, d
Sensitivity analysis
a 0.95 0.0003
b N/A
e
Percent of patients hospitalized due to infection 8.7 2.6 0.2423
c N/A
Sensitivity analysis
a 6.67 0.3925
c
Rate of days with antibiotics for treatment or
prophylaxis of infection (days/patient/year)
72.75 48.5 <0.0001
b <0.0001
b
Sensitivity analysis
a 66.62 <0.0001
b <0.0001
b
Rate of days missed off work/school due to infection
(days/patient/year)
8.0 2.06 <0.0001
b <0.0001
b
Sensitivity analysis
a 5.25 <0.0001
b <0.0001
b
Percent of patients missing ≥1 day off work/school
per year due to infection
43.5 31.6 0.2637
c N/A
Sensitivity analysis
a 42.2 0.3179
c
EU European Union, N/A not applicable, US United States
aSensitivity analysis of health outcomes after exclusion of one patient from the 1:1 cohort (EU) who suffered from recurrent pneumonia
bP-value from Poisson regression
cP value from Chi-square test
dThe factor PID type was dropped from the multi-factorial analysis for hospitalization due to convergence problems
eAnalysis not performed due to non-convergence of the model
Table IV Analysis of infection rates in the two cohorts of PID patients
1:1 dose cohort
(EU) (N046)
1.5:1 dose cohort
(US) (N038)
Analysis of differences
between cohorts
Number (%) of patients without infections in efficacy period 10 (21.7) 7 (18.4) 0.7064
a
Number (%) of patients with 1–4 infection episodes in efficacy period 24 (52.2) 24 (63.2) 0.3113
a
Number (%) of patients with >4 infection episodes in efficacy period 12 (26.1) 7 (18.4) 0.4032
a
Annualized rate of infection in patients with >4 infection episodes in efficacy period 12.05 8.38 0.0430
b
EU European Union, N/A not applicable, US United States
aP value from Chi-square test
bP value from Poisson regression
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Two independent trials of Hizentra® were conducted in the
USA and the EU with similar designs except that regulatory
authorities in the USA required that patients be converted to
a SC dose that was 1.5 times higher than the IV dose they
were previously using. The US FDA requested that SCIG
dose be adjusted to achieve an equivalent AUC of IgG
serum levels when patients were converted from monthly
IV dosing to weekly SC dosing. Calculations based on IgG
serum levels obtained from patients under IVIG indicated
that it would require a SC dose that was 1.5 times the IV
dose to achieve an equivalent AUC. On the other hand, the
European Medicines Agency (EMA) accepted the direct
conversion of the monthly IV dose to a weekly SC dose
by simple division of the monthly dose into weekly incre-
ments, as long as this resulted in non-inferior IgG levels
compared to the trough on previous therapy. Indeed, experts
disagreed when asked if IgG efficacy is driven by peak,
trough, or AUC serum levels [12]. As a result, two parallel
registration trials with similar designs were initiated with
different SCIG dose levels, creating a unique opportunity to
explore the effect of IgG dose on treatment outcomes in
stable well-managed PID patients.
By comparing the two cohorts, we found that the 1:1
and 1.5:1 doses of SCIG were equally effective in
achieving freedom from serious life-threatening bacterial
infections. However, we showed that in the 1.5:1 dose
(USA) cohort, there were significantly better function
(fewer work/school days missed), significantly less
health care utilization (fewer hospitalization days and
less antibiotic use), and a significantly lower rate of
non-serious infections. This two-cohort approach offers
some valuable insights and strongly suggests a positive
effect of 1.5:1 IgG dose on outcomes.
These findings should be interpreted with caution as the
comparison of results from two independent studies differs
from that of results collected in a single randomized trial.
Factors not controlled statistically or by randomization may
be contributing to the differences observed (baseline PID
severity, practice differences between the EU and the USA,
etc.). As the differences in behaviors (work/school atten-
dance, antibiotic use) correlated with differences in infection
rate, it seems unlikely that the improvement in clinical out-
comes in the US study was purely a function of the differ-
ences in patient behavior between the USA and the EU.
Also, there were several differences between the two studies
that might limit a direct side-by-side comparison. First,
the US study was longer than the EU study (54-week vs.
28-week efficacy period, respectively). Second, the pre-
specified primary endpoints were different. In the US study,
the primary endpoint was the annual rate of serious bacterial
infections, while in the EU study, the primary endpoint was
the total serum IgG trough level. Third, the EU study had
more pediatric and XLA patients, while the US study had a
larger sample size and a higher dropout rate (43% vs. 16%
for the EU study [14, 16]). Nevertheless, by controlling the
gender, age, and PID type as covariates, the significant
differences in all four study outcomes were confirmed,
thereby strongly suggesting that the differences in study
design and population were very unlikely responsible for
the better outcomes observed in the US cohort. Fourth, US
patients were treated with higher doses for a longer period of
time as they had received higher pre-study IgG doses (144
vs. 122 mg/kg in the EU study). However, this difference
does not change the overall result that the more IgG patients
received, the better indices of health they had.
An alternate explanation for these findings could be that
the PID patients enrolled in the USA had milder disease or
had better outcomes in their pre-study period compared to
the EU cohort. Unfortunately, no efficacy assessment was
done prior to study initiation to determine if the two groups
were similar at baseline.
In spite of these research design limitations, it is interest-
ing to note that these findings do not contradict previous
dose-ranging studies. Indeed, of the ten previously pub-
lished IgG dose–response studies [3, 18–26] summarized
in Table V, only the first two studies published in 1984 did
not show a dose-response relationship. None of the ten
studies identified a plateau or flattening in the dose–re-
sponse function at the top of the dose range above which
no further outcome improvement was achieved. Moreover,
it was recently shown by Orange et al., in a meta-analysis
that included 17 studies with 676 patients treated with IVIG
and 2,127 patient-years of follow-up, that pneumonia risk
was directly related to trough level of IgG and that this risk
could be progressively reduced by higher trough IgG levels
of up to at least 1,000 mg/dL [12]. Similarly, Berger showed
that the incidence of non-serious infections was inversely
proportional to the steady state serum IgG levels achieved in
different SCIG studies [11].
None of these studies assessed if the outcomes achieved
by patients from higher-dose groups were comparable to
healthy (non-PID) individuals with a “normal” rate of in-
fection or comparable to individuals with a state of “com-
plete physical, mental and social well being.” In our study,
the PID patients in the 1.5:1 dose group have missed 2.06
work/school days/patient/year due to infection alone. The
US Bureau of Labor Statistics reports that, on average, in
2010, US workers missed 2.3 days/year due to any infec-
tions, other illnesses, or injuries [26]. This would indicate
that PID patients treated with the 1.5:1 dose may still have
sub-optimal experience of normal activity if other reasons
for missed activity are considered. While all PID studies
focus on the lack of disease, specifically a reduction in the
rate of infections, not all include measures assessing the
286 J Clin Immunol (2012) 32:281–289extent to which a patient achieves the WHO definition of
health or some other measure of well being or function.
Efficacy measures such as antibiotic use, hospitalization
rate, and missed work/school days serve as clinical and
economic indicators in clinical trials; however, they do not
represent the total spectrum of the patient benefit which can
be achieved through optimal IgG dose. Other associated
patient benefit effects may be occurring with 1.5:1 IgG
doses, even if they were not measured. For example, a child
may not miss school with low-grade infections but cannot
partake in the more physical aspects of classroom and play-
ground life. An adult may not be so sick as to warrant time
off work, but persistently lacks the energy for a normal
social life. The 1.5:1 dose is therefore expected to be asso-
ciated with a greater normalcy of life experiences, moving
patients closer to a life without breakthrough infections or
chronic lack of well being. Moreover, the long-term sequelae
of frequent infections accumulate over time, leading to struc-
tural changes inlung or sinus tissue. Preventing such sequelae
may lead to further improvements in long-term patient
Table V A summary of the dose comparison studies of IgG in PID published to date
Publication Route IgG preparation Number of
patients
Study design Outcomes monitored Results Dose–response
relationship
found
Identified upper
dose with no
incremental benefit
a
Hill, 1971 [4] Not
available
Not available 176 Open-label 0.05 g/kg was
superior to 0.025 g/kg
(reduced frequency
of febrile episodes,
otitis media, and
pneumonia)
No No
Montanaro,
1984 [23]
IV Gamimune 10% 11 Randomized No patient outcomes,
time from 500 mg/kg
dose to serum level
under 400 mg/dL
150 and 500 mg/kg were
not differentiated
No
b N/A
Ochs, 1984
[20]
IV Gamimune 10% 35 Two-arm randomized,
12 month
Number of infections,
antibiotic use, days
missed
100 and 400 mg/kg are
equally effective
No N/A
Bernatowska,
1987 [24]
IV Endoglobulin 12 Two-arm randomized
cross-over with
retrospective vhistory,
12 month
Fever, infections,
antibiotic use, lung
function
500 mg/kg is superior to
150 mg/kg, especially in
children with more
symptoms
Yes No
Roifman,
1987 [21]
IV Sandoglobulin 12 Two-arm randomized
cross-over
Infections, lung
function
600 mg/kg is superior to
200 mg/kg; >500 mg/dL
is superior to <500 mg/dL
Yes No
Liese,
1992 [22]
IV, IM Various 29 Retrospective chart
review
Pneumonia, days
hospitalized
400 mg/kg q3 weeks IV is
superior to 200 mg/kg q3
weeks IVor 100 mg/kg
q3 weeks IM
Yes No
Pruzanski,
1996 [25]
IV Iveegam 21 Three-arm
randomized
Infections 600 or 400 mg/kg is
superior to 200 mg/kg;
Yes No
c
Quartier,
1999 [19]
IV Various 31 Retrospective chart
review
Hospitalization for
infection
>800 mg/dL is superior to
500–800 mg/dL or <500
mg/dL
Yes No
Eijkhout,
2001 [18]
IV Immunoglobulin
IV
43 Two-arm randomized
cross-over, 9 month
Infection rate and
duration
600/800 mg/kg is superior
to 300/400 mg/kg; 940
mg/dL is superior to 630
mg/dL
Yes No
Roifman,
2003 [3]
IV Gamunex, 10% 73 Findings based on
post-hoc analysis
of data
Infection rate >900 mg/dL is superior to
>700–900 mg/dL; >700–
900 mg/dL is superior to <
700 mg/dL
Yes No
Gamimune-N 10% 73
Favre,
2005 [28]
IV Sandoglobulin 7 Observational, 116
patient-years
Infections 400 mg/kg q3 weeks is
superior to 200 mg/kg
q3 weeks
Yes No
This study SC Hizentra 84 Open-label, multi-
center, single-arm
Infections, missed
work/school
days due to
infection,
hospitalization days
due to infection, and
days of antibiotic
therapy
Mean weekly IgG dose of
120 mg/kg improved
secondary efficacy
outcomes compared to
213 mg/kg
Yes, for some
outcomes
No
IV intravenous, IM intramuscular, N/A not applicable
aThis pertains to the flat portion of the dose–response curve where an increase in the dose is not associated with any additional clinical response
bNo response or outcomes were monitored, only effect of dose on serum levels
cThe dose–response pattern observed was not consistent with a normal dose–response relationship, in that the highest dose had inferior outcomes to
the lowest dose
J Clin Immunol (2012) 32:281–289 287outcomes and potential reductions in long-term health care
costs.HigherIgGdosesmayalsohelpreducethefrequencyof
chronic infections. Living a life with fewer infections may
offer opportunities for PID patients which may otherwise not
be afforded.
Conclusions
The objectives of PID treatment continue to evolve. Suc-
cessful treatment can no longer be measured solely by the
degree to which serious bacterial infections are prevented.
Other clinical and functional outcomes must be measured as
well. The findings that we report here suggest that increas-
ing the doses of IgG might produce improvements in such
outcomes, at least in some patients with frequent infections.
As the agenda of treatment of PID patients move forward
beyond life or death interventions, the goals of IgG therapy
may move toward optimization of health state outcomes and
the full achievement of health and a normal life. The higher-
dose cohort in this comparison recorded improved indices of
well being compared to those treated with traditional doses
of IgG. This study, despite its limitations, suggests that
increasing the SCIG doses is associated with significantly
fewer infections, days of hospitalization, days of antibiotic
use, and days of missed activities, resulting in reduced
resource utilization.
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